Dec 14, 2019: Takeda and MiTest Health LLC a pioneering health technology company, announced an exclusive partnership to optimize MiTest’s personalized risk and outcome prediction tool for the widespread use in patients with Crohn’s disease (CD).
The validated tool can help predict a patient’s individual potential risk for CD-related complications based on the clinical, serologic and genetic variables and create a visual report to support informed and shared decision-making with their healthcare providers.
Overwhelming complications from CD – such as fistulas, abscesses, strictures, and intestinal obstruction are common, so far the course of CD is highly variable and difficult to predict.
These validated predictive tool was developed by MiTest in 2014 and validated via analysis of a well-characterized cohort of adult patients with CD and predictive modelling and has been used on a limited basis in clinical settings to date.
Takeda will also provide support in scaling up and operationalizing the tool to be more broadly support providers and patients. https://www.takeda.com/en-us/newsroom/news-releases/2019/takeda-partners-with-mitest-health-to-launch-innovative-disease-risk-prediction-tool/
